Rituximab: A Breakthrough Therapy For Myasthenia Gravis: Targeting Immune Dysfunction For Symptom Relief
Rituximab, a monoclonal antibody, depletes B cells in myasthenia gravis, an autoimmune disorder causing muscle weakness due to acetylcholine receptor antibodies. Rituximab’s mechanism targets B cells, reducing pathogenic antibody production and inflammation. Clinical studies have demonstrated its effectiveness in improving muscle strength and reducing symptoms, highlighting its role as a therapeutic option. By targeting immune…